semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 2.0-16.0,  Asthma Acute Asthma Ages 2 to 16 years Background history of asthma as defined by at least one previous episode of ß2-agonist-responsive wheeze in a child two years of age or over or a prior diagnosis of asthma, made by a pediatrician, or clinician of comparable experience Presentation with an asthma exacerbation as defined as acute asthma, which prompts assessment at the ED, and has any, or all, of the following clinical features: Dyspnea, Wheeze, Acute cough, Increased work of breathing, Increased requirement for ß2-agonist from baseline use or O2 saturation <95%  Less than 2 years old or over 16 years Critical or life-threatening asthma (as defined below) Known TB exposure Active varicella or herpes simplex infection Documented concurrent infection with RSV Fever >39.5°C Use of oral corticosteroids in the previous four weeks Concurrent stridor Galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-21.0,  Asthma Asthma Attack Asthma, Allergic Ages 12 to 21 years, inclusive, of both genders 2. Physician diagnosis of persistent asthma or symptoms consistent with persistent asthma based on NHLBI Expert Panel Review 3 guidelines for diagnosis and management of asthma. 3. Current use of a controller therapy such as an inhaled corticosteroid (ICS), ICS in combination with long-acting beta agonist (LABA), or leukotriene receptor antagonist (LTRA). 4. A history of at least one asthma exacerbation requiring oral corticosteroids (OCS) in the past 12 months. 5. Wireless internet access in the participant's home  Systemic corticosteroid-dependent asthma (i.e. people who take oral steroids such as prednisone daily for asthma control). 2. Pulmonary disease other than asthma that in the opinion of investigators may affect the interpretation of spirometry data, including but not limited to vocal cord dysfunction, restrictive lung disease, or cystic fibrosis. 3. Inability to perform spirometry. 4. History of spirometry-induced bronchoconstriction. 5. Pregnancy or nursing a baby
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Men or women age 18 or older; 2. Treatment with inhaled corticosteroids (ICS) +/ long acting β-agonists/long acting muscarinics and montelukast; 3. Physician diagnosed asthma; 4. Forced expiratory volume (FEV1) ≥60% of predicted 5. Methacholine PC(20) < 16 mg/ml if taking ICS and < 8mg/ml if not taking ICS at Visit 2. 6. Non-smoker (e.g., tobacco, e-cigarette, marijuana) for ≥1 yr.; 7. ≤10 pack-year smoking history; 8. Suboptimal control of asthma as determined by a score < 19 or less on the Asthma Control Test (ACT) at Screening Visit (Visit 1) and Randomization Visit (Visit 3)  Other major chronic illnesses: Conditions which in the judgment of the study physician would interfere with participation in the study, e.g., non-skin cancer, uncontrolled diabetes mellitus, coronary artery disease, congestive heart failure, stroke, severe hypertension, renal failure, liver disorders, malabsorption disorders, immunodeficiency states, major neuropsychiatric disorder; 2. Cardiovascular problems: Myocardial infarction or stroke in last 3 months Uncontrolled hypertension Known aortic aneurysm 3. History of physician diagnosis of chronic bronchitis, emphysema or chronic obstructive pulmonary disease (COPD) 4. Medication use: Current consumption of ginger supplements, oral corticosteroid use within the past 6 weeks, use of an investigational treatment in the previous 30 days, known adverse reaction to ginger or ginger products; 5. Females of childbearing potential: Pregnant or lactating; participants of appropriate age who might be pregnant at the time of enrollment will be screened with urine pregnancy tests at each visit and cannot participate if pregnant. Participants must agree to use effective contraception during the trial. 6. Inability to perform acceptable and repeatable spirometry maneuvers throughout the test procedure
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 13.0-81.0,  Asthma Provision of signed and dated written informed consent Negative urine test for female subjects of childbearing potential prior to administration of IP at visit 1 Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception from screening, and must agree to continue using such precautions for 16 weeks after the final dose of IP Female or male subjects who have not met investigational product discontinuation and have attended the EOT visit in either study D5180C00007 (NAVIGATOR) or D5180C00009 (SOURCE) To enter the extended follow-up phase of the study, the following also apply Provision of signed and dated Addendum for Extended Follow-up to informed consent, as well as assent by adolescent subjects where applicable, prior to any mandatory study specific procedures, sampling and analyses before Extended Follow Up Must have entered from D5180C00007 study and have completed IP dosing to Week 100, have not met IP Discontinuation and have attended the EOT Visit  Any clinically important pulmonary disease other than asthma Any disorder, including, but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable History of chronic alcohol or drug abuse within 12 months prior to visit 1 Current malignancy or malignancy that developed during a predecessor study Major surgery or planned surgical procedures requiring general anesthesia or inpatient status for > 1 day during the conduct of the study Treatment with systemic immunosuppressive/immunomodulating drugs except for OCS used in the treatment of asthma/asthma exacerbations within the last 12 weeks prior to randomization Concurrent enrolment in another clinical study involving an IP Any clinically meaningful abnormal finding in physical examination, vital signs, ECG,haematology, clinical chemistry, or urinalysis during the predecessor study Pregnant, breastfeeding, or lactating To enter the extended follow-up phase of the study (which extends from week 104 to week 140), the following also apply
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Oxygen Toxicity Hyperoxia and older patients scheduled for 60 HBOT sessions for any indication  Active smokers were excluded but patients who quit smoking more than six months prior to were allowed in the study active smoking severe known pulmonary disease chest pathology incompatible with HBOT inner ear disease claustrophobia other neurological conditions pregnancy previous HBOT within six months prior to the inability to sign informed consent
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma control subjects = non-atopic and non-smoking cutting to negative pneumoallergens Total IgE levels less than 100 ku / L no clinical history of asthma without background treatment 2. patients with intermittent asthma = being asymptomatic between asthma attacks with symptoms less than once a week having a forced expiratory volume per second (FEV1) of at least 80% of the theoretical treated by ß2 mimetics on demand and will not have inhaled corticosteroids. 3. severe asthma insensitive to corticosteroid therapy =  existence of a chronic inflammatory pathology other than asthma active smoking pregnant or lactating women have received oral corticosteroid treatment in the previous 3 weeks have received non-steroidal anti-inflammatory drugs (NSAIDs) in the previous 2 weeks
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 7.0-999.0,  Duchenne Muscular Dystrophy Cardiomyopathy, Dilated Older than(including) 7 years old A definite diagnosis of DMD with muscle pathology confirming the expression of dystrophin lower than 5% and/or confirmed mutations in the DMD gene using a clinical accepted technique that completely defines the mutation Using ACEI or ARB for more than 1 month Confirmed myocardial damage in one or more left ventricular segments evident by late gadolinium enhancement and preserved left ventricular systolic function(>45%) by cine cardiac MR in 45 days Normal renal function Holter and blood pressure shows no contraindication of using bisoprolol  Having metal implanted in body Having claustrophobia Allergic to gadolinium Complicated with other cardiovascular diseases Medical history or Holter show bradyarrhythmia like II/III degree atrioventricular block, sick sinus syndrome etc Systolic blood pressure lower than 90mmHg or rest heart rate lower than 75bpm Having COPD or asthma history Having other complications: tumor, endocrine diseases Having beta blockers therapy Planned operation in the future 12 months
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Asthma Atopic Age range 18-45 years, inclusive FEV1 of at least 80% of predicted and FEV1/FVC (Forced Vital Capacity) ratio of at least 0.7 (without use of bronchodilator medications for 8 hours or long acting beta agonists for 24 hours), consistent with lung function of persons with no more than mild episodic or mild persistent asthma Physician diagnosis of asthma Allergic sensitization to felis catus (cat hair) as confirmed by positive immediate skin prick test response Negative pregnancy test for females who are not s/p hysterectomy or who have been amenorrheic for 12 months or more Oxygen saturation of >94% and blood pressure within the following limits: (Systolic between 150-90 mmHg, Diastolic between 90-60 mmHg)  Clinical contraindications Any chronic medical condition considered by the PI as a contraindication to participation in the study including significant cardiovascular disease, diabetes, chronic renal disease, chronic thyroid disease, history of chronic infections or immunodeficiency Physician directed emergency treatment for an asthma exacerbation within the preceding 12 months Exacerbation of asthma more than 2x/week which could be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma Daily requirements for albuterol due to asthma symptoms (cough, wheeze, chest tightness) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma (not to prophylactic use of albuterol prior to exercise) Viral upper respiratory tract infection within 4 weeks of challenge Any acute infection requiring antibiotics within 6 weeks of exposure or fever of unknown origin within 6 weeks of challenge Severe asthma Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements Cigarette smoking >1 pack per month
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Asthma Chronic mild or moderate asthma with a stable course of at least 3 months symptoms less than 4x per week use of SABA below 3x a week night awakening below 1x per week FEV1> 80% of predicted no dose change in ICS or use of systemic steroids from 3 months good adherence to treatment  infection or exacerbation of asthma requiring the use of systemic steroids (or changes in the dose of inhaled steroids) in the last 3 months before the study other chronic lung diseases or general diseases affecting the respiratory system tobacco smoking FEV1 below 80% of the predicted value
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Hypertension, Pulmonary Patient with idiopathic pulmonary hypertension (PH), familial PH, or PH associated with various pathologies (groups I to IV of the international classification) New York Heart Association (NYHA) severity classes II to IV Incident cases, or prevalent cases with stable disease over the last 3 months Collection of informed written consent Affiliation with or beneficiary of a social security program (health insurance) Outpatient consulting at the hospital on the day of minute walking test on day of  Patients protected or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP) Pregnant or lactating women according to article L1121-5 of the CSP Vulnerable persons according to article L1121-6 of the CSP Simultaneous participation in any other research protocol It is impossible to correctly inform the patient (language barrier, etc.) The patient has already been included in the study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Oligohydramnios Pregnant women between 24-37 weeks of gestation, single fetus, who were diagnosed with an amniotic fluid index at the 5th percentile or below, according to the current gestational age No medical indication for immediate delivery  Refusal to participate in the study A medical recommendation for delivery within two weeks of diagnosis Fetal malformation or proof of fetal infection that known to cause oligohydramnios (eg CMV) Premature rupture of membrane Multiple pregnancy Medical contraindication to the low-salt diet
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 40.0-89.0,  Persistent Cough in IPF Chronic Cough IPF Male or female subjects age 40 through 89 years Confirmed diagnosis of IPF with clinical features consistent with the current clinical practice guidelines Persistent cough for at least 8 weeks that is primarily due to IPF and not responsive to anti-tussive therapy Daytime cough severity score of ≥ 40 mm on a 100-mm VAS hour average cough count of at least 10 coughs per hour Forced Vital Capacity (FVC) > 45% predicted value within 4 weeks Diffusion capacity for carbon monoxide corrected for hemoglobin (DLCOc) > 30% predicted value within 4 weeks Life expectancy of at least 12 months  Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could place the subject at risk or compromise the quality of the study data Significant coronary artery disease (i.e., myocardial infarction within 6 months or unstable angina within 1 month) Upper or lower respiratory tract infection within 4 weeks Acute exacerbation of IPF within 6 months Lung transplantation expected within 12 months Requiring supplemental O2 > 4 litres/min to maintain peripheral arterial O2 saturation (SpO2) > 88% at rest History of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 2 years Current smoker (i.e., use of tobacco products within the last 3 months) Current or recent history of drug or alcohol abuse within 12 months Participation in any other investigational drug study within 4 weeks
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Allergic Diseases An adult pregnant mother who is over 20 years old and has a history of asthma or eczema or allergic rhinitis who is exercising autonomous consent Pregnant women over 20 years old without allergies Infants ≧ 37 weeks gestational age  Under 20 years old Pregnant mothers and babies with congenital immune diseases